EUVIMEDEUVIMED entdecken
Open Access

Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients

Alexandra Amaducci, Kim Aldy, Sharan L Campleman, Shao Li, Alison Meyn, Stephanie Abston, Rachel E Culbreth, Alex Krotulski, Barry Logan, Paul Wax, Jeffrey Brent, Alex F Manini und 1 weitere

JAMA Network Open · 29.08.2023 · 6 (8) · e2331264

DOI: 10.1001/jamanetworkopen.2023.31264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 29.08.2023. Verfasst von Alexandra Amaducci und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lehigh Valley Health Network-USF Morsani College of Medicine, Allentown, Pennsylvania. Hauptthemen laut MEDLINE: Opiate Overdose, Drug Overdose. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Synthetic opioids, such as the fentanyl analogue and nitazene drug class, are among the fastest growing types of opioids being detected in patients in the emergency department (ED) with illicit opioid overdose (OD). However, clinical outcomes from OD of novel potent opioids (NPOs), specifically nitazenes, are unknown aside from small case series.

Objective

To determine naloxone administration and clinical sequelae of patients who were in the ED with NPO overdose compared with fentanyl OD. Design, Setting, and Participants This is a cohort study subgroup analysis of adults admitted to the ED and tested positive for NPOs among in the ongoing nationwide ToxIC Fentalog cohort study from 2020 to 2022. Patients who were in the ED with a presumed acute opioid OD and residual blood samples were included, and those testing positive for NPOs were analyzed. Patients were included in this analysis if their confirmatory testing was positive for an NPO analyte, such as brorphine, isotonitazene, metonitazene, and/or N-piperidinyl etonitazene. A comparison group included patients that were positive for fentanyl and devoid of any other analytes on toxicologic analysis. Exposures Patients were exposed to NPOs, including brorphine, isotonitazene, metonitazene and/or N-piperidinyl etonitazene. Main Outcomes and Measures The primary outcome was the total number of naloxone doses and total cumulative naloxone dose administered as part of routine clinical care following the OD. Naloxone requirements and clinical sequelae of NPO-positive patients were compared with those testing positive for fentanyl only.

Results

During the study period, 2298 patients were screened, of whom 717 met inclusion criteria, 537 had complete laboratory testing data, with 11 (2.0%) positive for only fentanyl and 9 (1.7%) positive for NPOs (brorphine, isotonitazene, metonitazene, or N-piperidinyl etonitazene). The age range of patients was aged 20 to 57 years (4 males [44.4%] and 5 females [55.6%]). The NPO group received a statistically significantly higher mean (SD) number of naloxone boluses in-hospital (1.33 [1.50]) compared with the fentanyl group (0.36 [0.92]) ( P = .02), which corresponded to a moderately large effect size (Cohen d = 0.78). Metonitazene overdose was associated with cardiac arrest and more naloxone doses overall. Metonitazene cases had a mean (SD) number of 3.0 (0) naloxone doses, and 2 of 2 patients (100%) with metonitazene overdoses were administered cardiopulmonary resuscitation. Conclusions and Relevance In this cohort study of patients admitted to the ED with confirmed opioid overdose testing positive for NPOs, in-hospital naloxone dosing was high compared with patients who tested positive for fentanyl alone. Further study is warranted to confirm these preliminary associations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opiate OverdoseDrug OverdoseAdultFemaleMaleHumansYoung AdultMiddle AgedAnalgesics, OpioidCohort StudiesFentanylDisease ProgressionEmergency Service, HospitalAmines

Substanzen

Analgesics, OpioidFentanylmetonitazeneAmines

Autor:innen und Institutionen

  • Lehigh Valley Health Network-USF Morsani College of Medicine, Allentown, Pennsylvania.
  • American College of Medical Toxicology, Phoenix, Arizona.
  • Baylor University Medical Center, Dallas, Texas.
  • Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, Pennsylvania.
  • NMS Labs, Horsham, Pennsylvania.
  • University of Texas Southwestern Medical Center, Dallas.

Förderung

  • NIDA NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Amaducci, A., Aldy, K., Campleman, S. L., Li, S., Meyn, A., Abston, S., Culbreth, R. E., Krotulski, A., Logan, B., Wax, P., Brent, J., Manini, A. F., & Toxicology Investigators Consortium Fentalog Study Group (2023). Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Network Open, 6(8), e2331264. https://doi.org/10.1001/jamanetworkopen.2023.31264

Vancouver

Amaducci A, Aldy K, Campleman SL, Li S, Meyn A, Abston S, et al. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Network Open. 2023;6(8):e2331264. doi:10.1001/jamanetworkopen.2023.31264

BibTeX
@article{Amaducci2023,
  author = {Amaducci, Alexandra and Aldy, Kim and Campleman, Sharan L and Li, Shao and Meyn, Alison and Abston, Stephanie and Culbreth, Rachel E and Krotulski, Alex and Logan, Barry and Wax, Paul and Brent, Jeffrey and Manini, Alex F and Toxicology Investigators Consortium Fentalog Study Group, Toxicology Investigators Consortium Fentalog Study Group},
  title = {Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {8},
  pages = {e2331264},
  doi = {10.1001/jamanetworkopen.2023.31264}
}
Kostenlos starten →